Chengdu Olymvax Biopharmaceuticals Inc
SSE:688319
Intrinsic Value
Chengdu Olymvax Biopharmaceuticals, Inc. engages in the research and development, manufacture, and sale of human-use vaccines. [ Read More ]
The intrinsic value of one
Chengdu Olymvax Biopharmaceuticals Inc
stock under the Base Case scenario is
10.7
CNY.
Compared to the current market price of 9.47 CNY,
Chengdu Olymvax Biopharmaceuticals Inc
is
Undervalued by 12%.
Chengdu Olymvax Biopharmaceuticals Inc's market capitalization is 3.8B CNY.
Chengdu Olymvax Biopharmaceuticals Inc stock price is 9.47 CNY.
Chengdu Olymvax Biopharmaceuticals Inc stock price (9.47 CNY) is 12% less than its Intrinsic Value (10.7 CNY).
Chengdu Olymvax Biopharmaceuticals Inc stock (6.11 CNY) is 36% less than its price (9.47 CNY). Open DCF Valuation
Chengdu Olymvax Biopharmaceuticals Inc stock price (9.47 CNY) is 38% less than its Relative Value (15.3 CNY). Open Relative Valuation
Chengdu Olymvax Biopharmaceuticals Inc has upside potential of 154% compared to the average analyst price target.
Open Wall St Estimates
Chengdu Olymvax Biopharmaceuticals Inc's Revenue has dropped by 0% over the past 12 months.
Chengdu Olymvax Biopharmaceuticals Inc has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
Chengdu Olymvax Biopharmaceuticals Inc has positive Operating Income for the last twelve months.
Chengdu Olymvax Biopharmaceuticals Inc has positive Net Income for the last twelve months.
Chengdu Olymvax Biopharmaceuticals Inc has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
Chengdu Olymvax Biopharmaceuticals Inc's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
Chengdu Olymvax Biopharmaceuticals Inc's ROIC (Return on Invested Capital) has decreased in the last 3 years from 10% to 2%.
Chengdu Olymvax Biopharmaceuticals Inc's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 2%.
Chengdu Olymvax Biopharmaceuticals Inc's Revenue is forecast to grow at a rate of 12% per year over the next 3 years.
Chengdu Olymvax Biopharmaceuticals Inc's ROE (Return on Equity) has significantly decreased in the last 3 years from 14% to 3%.
Chengdu Olymvax Biopharmaceuticals Inc's short-term assets (912m CNY) exceed its short-term liabilties (450m CNY).
Chengdu Olymvax Biopharmaceuticals Inc has negative Net Debt. This means that the company has more cash and short-term investments (320m CNY) than debt (148m CNY).
Chengdu Olymvax Biopharmaceuticals Inc's long-term assets (1B CNY) exceed its long-term liabilties (570m CNY).
Chengdu Olymvax Biopharmaceuticals Inc has positive Gross Profit for the last twelve months.
Chengdu Olymvax Biopharmaceuticals Inc has negative Free Cash Flow for the last twelve months.
Chengdu Olymvax Biopharmaceuticals Inc's D/E (Debt to Equity) is very low and is equal to 0.16.
Chengdu Olymvax Biopharmaceuticals Inc's Altman Z-Score is very high and is equal to 9.75.
Valuation Backtest
Chengdu Olymvax Biopharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
Chengdu Olymvax Biopharmaceuticals Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Chengdu Olymvax Biopharmaceuticals Inc
Balance Sheet Decomposition
Chengdu Olymvax Biopharmaceuticals Inc
| Current Assets | 912.4m |
| Cash & Short-Term Investments | 319.8m |
| Receivables | 493.6m |
| Other Current Assets | 99m |
| Non-Current Assets | 569.7m |
| PP&E | 393.5m |
| Intangibles | 157.3m |
| Other Non-Current Assets | 18.9m |
| Current Liabilities | 449.8m |
| Accounts Payable | 34.4m |
| Accrued Liabilities | 4.6m |
| Short-Term Debt | 61.7m |
| Other Current Liabilities | 349.1m |
| Non-Current Liabilities | 120.3m |
| Long-Term Debt | 86.3m |
| Other Non-Current Liabilities | 34m |
Earnings Waterfall
Chengdu Olymvax Biopharmaceuticals Inc
|
Revenue
|
548m
CNY
|
|
Cost of Revenue
|
-41.4m
CNY
|
|
Gross Profit
|
506.6m
CNY
|
|
Operating Expenses
|
-475.7m
CNY
|
|
Operating Income
|
30.9m
CNY
|
|
Other Expenses
|
-6.8m
CNY
|
|
Net Income
|
24.1m
CNY
|
Free Cash Flow Analysis
Chengdu Olymvax Biopharmaceuticals Inc
| CNY | |
| Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Chengdu Olymvax Biopharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Chengdu Olymvax Biopharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Chengdu Olymvax Biopharmaceuticals Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Chengdu Olymvax Biopharmaceuticals Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Chengdu Olymvax Biopharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
Chengdu Olymvax Biopharmaceuticals Inc
is 24.04 CNY
.
Shareholder Return
Price
Chengdu Olymvax Biopharmaceuticals Inc
| Average Annual Return | -34.56% |
| Standard Deviation of Annual Returns | 33.88% |
| Max Drawdown | -82% |
| Market Capitalization | 3.9B CNY |
| Shares Outstanding | 406 158 016 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Chengdu Olymvax Biopharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Chengdu Olymvax Biopharmaceuticals, Inc. engages in the research and development, manufacture, and sale of human-use vaccines. The company is headquartered in Chengdu, Sichuan and currently employs 440 full-time employees. The company went IPO on 2021-06-08. The firm's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The firm's main customers are center for disease control and prevention (CDC) customers.
Contact
IPO
Employees
Officers
The intrinsic value of one
Chengdu Olymvax Biopharmaceuticals Inc
stock under the Base Case scenario is
10.7
CNY.
Compared to the current market price of 9.47 CNY,
Chengdu Olymvax Biopharmaceuticals Inc
is
Undervalued by 12%.
You don't have any saved screeners yet
